[go: up one dir, main page]

WO2000074658A1 - Utilisation de nanoparticules chargees de medicament dans le traitement anticancereux - Google Patents

Utilisation de nanoparticules chargees de medicament dans le traitement anticancereux Download PDF

Info

Publication number
WO2000074658A1
WO2000074658A1 PCT/EP1999/003838 EP9903838W WO0074658A1 WO 2000074658 A1 WO2000074658 A1 WO 2000074658A1 EP 9903838 W EP9903838 W EP 9903838W WO 0074658 A1 WO0074658 A1 WO 0074658A1
Authority
WO
WIPO (PCT)
Prior art keywords
nanoparticles
treatment
mammal
cancer
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1999/003838
Other languages
English (en)
Inventor
Bernhard A. Sabel
Jörg KREUTER
Svetlana Gelperina
Ulrike SCHRÖDER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medinova Medical Consulting GmbH
Original Assignee
Medinova Medical Consulting GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medinova Medical Consulting GmbH filed Critical Medinova Medical Consulting GmbH
Priority to EP99926509A priority Critical patent/EP1100475A1/fr
Priority to JP2001501195A priority patent/JP2003501379A/ja
Priority to PCT/EP1999/003838 priority patent/WO2000074658A1/fr
Priority to AU43734/99A priority patent/AU4373499A/en
Publication of WO2000074658A1 publication Critical patent/WO2000074658A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to the use of drug-loaded nanoparticles for preparing a medicament for the treatment of cancer, particularly for the treatment of cancer in the brain, even more particularly for the treatment of brain cancer in humans.
  • the invention also relates to a process for the treatment of brain cancer, particularly for the treatment of brain cancer in humans, by ad ⁇ iinistering an effective amount of nanoparticles containing a substance which has effect in the cancer treatment or has immunosuppressive effects.
  • blood brain barrier refers to the bbb in the narrower sense, i. e. in the sense this term is used usually by a person skilled in the medical field, as well as to the blood spinal barrier and blood retina barrier.
  • nanoparticles prepared in accordance with teachings of the prior art, particularly of the above two Patent Applications may be loaded with a substance having effect in the treatment of cancers, particularly having effect in the treatment of cancers in the brain, for example in humans, in an effective amount and may then be coated with a suitable surfactant so as to allow that drug-loaded nanoparticles to pass across the bbb and to deliver the effective drug to the site where it may exhibit its anticancer and/or immunosuppressive activity. It was particularly found that, by a suitable selection of the combination drug/surfactant, an effective use of such nanoparticles loaded with the drug and coated with a surfactant in the treatment of cancers, particularly of cancers in the brain, may be pro viced.
  • the invention relates to the use of nanoparticles made of a polymeric material, said nanoparticles comprising said polymeric material, one or more substance(s) physiologically effective in the treatment of cancer upon delivery to a mammal, one or more stabilizer(s) for said nanoparticles allowing targeting of said physiologically effective substance(s) to a specific site within or on said mammalian body and/or a surfactant coating on said nanoparticles, said nanoparticles optionally being provided within a physiologically acceptable carrier and/or diluent allowing the delivery of said nanoparticles to the target within said mammal after administration, for the manufacture of a medicament for the treatment of cancer in said mammal.
  • the treatment of cancer is a treatment of cancer in the brain.
  • the brain cancer treatment is a treatment to a human.
  • the terms "cancer” and “tumor(s)” are used in the description and claims in a synonymous manner.
  • the nanoparticles used in the present invention for the cancer treatment are nanoparticles which mainly consist of three major components, i. e. the polymeric material which is used to form a wall either incorporating the drug or physiologically effective substance(s) or containing said substance(s) adsorbed or absorbed thereto, e. g. onto its surface; the physiologically effective substance or substances contained within or on said nanoparticle; and a stabilizer or more than one stabilizer allowing the passage of said nanoparticle across the bbb.
  • the present invention comprises as one of the preferred embodiments the use of said nanoparticles, wherein said nanoparticles comprise particles of said polymeric material having a diameter of below 1,000 nm, preferably of from 1 to 1,000 nm.
  • the invention relates to the use of said nanoparticles, wherein said polymeric material the nanoparticles are consisting of is selected from the group consisting of polyacrylates, polymethacrylates, poly-cyanoacrylates, polyacrylamides, polylactates, polyglycolates, polyanhydrates, polyorthoesters, gelatin, polysaccharides, -dbumin, polystyrenes, poly vinyls, polyacro ⁇ ein, polyglutaraldehydes and derivatives, copolymers and rnixtures thereof.
  • polyacrylates polymethacrylates, poly-cyanoacrylates, polyacrylamides, polylactates, polyglycolates, polyanhydrates, polyorthoesters, gelatin, polysaccharides, -dbumin, polystyrenes, poly vinyls, polyacro ⁇ ein, polyglutaraldehydes and derivatives, copolymers and rnixtures thereof.
  • the nanoparticles according to the invention there is/are provided within or on said nanoparticles (incorporated, absorbed and/or adsorbed) one or more substances which are physiologically effective in the treatment of cancer upon delivery to a mammal.
  • the substances may be a single substance or may be two or even more substances which may act on the human body on a separate route or on a combined route or even synergistic route.
  • said physiologically effective substance(s) to be delivered to said mammal comprise(s) one or more chemotherapeutic agent(s) for the cancer treatment, particularly for the treatment of cancer in the brain of said mammal, more particularly for the treatment of cancer in the human body, i. e. the brain.
  • chemotherapeutic agent(s) for the cancer treatment particularly for the treatment of cancer in the brain of said mammal, more particularly for the treatment of cancer in the human body, i. e. the brain.
  • chemotherapeutic anticancer agent is selected from the group consisting of alkylating agents, antimetabolites, natural anticancer products, hormones, metal coordination complexes and mixtures thereof.
  • chemotherapeutic anticancer agent is selected from the group consisting of alkylating agents, antimetabolites, natural anticancer products, hormones, metal coordination complexes and mixtures thereof.
  • nitroso ureas e. g. Carmustine (BCNU), Lomustine (CCNU), Semustine (methyl- CCNU) and Nimustine (ACNU);
  • BCNU Carmustine
  • CCNU Lomustine
  • CCNU Semustine
  • ACNU Nimustine
  • folic acid analogs e. g. Methotrexate
  • - purine analogs e. g. Mercaptopurine and Azathioprine
  • - vinca alkaloids e. g. Vinblastine, Nincristine and Vindesine
  • epipodophyllotoxins e. g. Etoposide and Teniposide
  • antibiotics e. g. Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Bleomycin A2, Mitomycin C and Mitoxantrone;
  • - estrogens e. g. Diethyl stilbestrol
  • - gonadotropin-releasing hormon analogs e. g. Leuprolide, Buserelin and Goserelin
  • antiestrogens e. g. Tamoxifen and Ammoglutethimide
  • mixtures of the above substances may also be used as long as they result into a successful treatment of cancer, particularly of brain cancer, in mammals as for example in humans.
  • Particularly preferred in the use of the nanoparticles of the p ⁇ resent invention are Doxorubicin and/or Mitoxantrone, since the administration of any of these substances by using nanoparticles results into a successful anticancer treatment, particularly a successful treatment of brain tumors in niammals as for example in humans.
  • a passage of the bbb by said substance in a therapeutically effective amount was observed, which fact was completely surprising for a skilled person being familiar with the prior art problem of providing a therapeutically effective amount of said anticancer agents in the brain.
  • a critical component of the nanoparticles used in the present invention is/are the stabilizer(s).
  • only one stabilizer is used whereby a passage of the bbb by said nanoparticles loaded with the anticancer drugs can be afforded in a successful way, and the anticancer drugs in said nanoparticles are directed to the tumor site in the brain in a high concentration.
  • the other critical component of the nanoparticles used in the present invention are the surfactant materials of the coating which materials are belonging to the same group of compounds as the above.
  • the stabilizer may be present in the nanoparticles used in accordance with the present invention as a result of the manufacturing steps either in small remaining amounts or may form the coating allowing the passage of the effective substance(s) across the bbb.
  • the separate coating may be provided.
  • the outside wall of the nanoparticles used in the present invention is coated with the material allowing the passage of the bbb in a surprising manner.
  • the application of the coating or the provision of the stabilizer in such nanoparticles is basically described in the above-mentioned International Patent Applications the disclosures of which are incorporated herein by reference.
  • the material(s) of the stabilizer/ surfactant is/are selected selected from the group consisting of stabilizers/surfactants which allow a passage of said nanoparticles including said physiologically effective substance(s) across the blood brain barrier in said mammal and stabilizers/surfactants which allow a release of said physiologically effective substance(s) from said nanoparticles and a passage of said substance(s) across the blood brain barrier separate from said nanoparticles.
  • said stabilizer/surfactant comprises a substance selected from the group consisting of polysorbates, dextrans, carboxylic acid esters of multifunctional alcohols, polyoxamers, polyoxamines, alkoxylated ethers, alkoxylated esters, alkoxylated mono-, di- and triglycerides, alkoxylated phenols and diphenols, substances of the Genapol R and Bauki R series, metal salts of carboxylic acids, metal salts of alcohol sulfates, and metal salts of sulfosuccinates and mixtures of two or more of said substances.
  • said stabilizer/surfactant comprises a substance selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, polysorbate 81, polysorbate 85, dextran 12.000, dextran 70,000, fatty acid esters of glycerol and sorbitol as glycerol monostearate, sorbitan monostearate and sorbitan monooleate, polyoxamer 188 (Pluronic R F68), ethoxylated ethers, ethoxylated esters, ethoxylated triglycerides, ethoxylated phenols and diphenols, metal salts of fatty acids and of fatty alcohol sulfates, more preferably the sodium salts of fatty acids and of fatty alcohol sulfates
  • the most preferred stabilizers/surfactant materials are selected from the group consisting of polysorbate 80, polysorbate 85, dextran 12,000 or dextran 70,000 and mixtures thereof and mixtures of said stabilizers with other stabilizers. With the latter compounds, a superior use of the nanoparticles in the anticancer treatment can be achieved, particularly in the treatment of brain cancers in humans.
  • said carrier and/or diluent which is used for the aclministration of the nanoparticles used in the present invention is/are selected from the group consisting of water, physiologically acceptable aqueous solutions containing salts and/or buffers and any other solution acceptable for administration to a mammal.
  • nanoparticles comprising said polymeric material, one or more substance(s) physiologically effective in the treatment of cancer upon delivery to a mammal, one or more stabilizer(s) for said nanoparticles allowing targeting of said physiologically effective substance(s) to a specific site within said mammalian body and/or a surfactant coating on said nanoparticles, said nanoparticles optionally being provided within a physiologically acceptable carrier and/or diluent allowing the delivery of said nanoparticles to the target within said mammal after administration, for the treatment of cancer in said mammal.
  • a process for the treatment of cancer particularly of brain cancer, in mammals, said process comprising the step of administering to said mammals nanoparticles made of a polymeric material, said nanoparticles comprising said polymeric material, one or more substance(s) physiologically effective in the treatment of cancer upon delivery to a mammal, one or more stabilizer(s) for said nanoparticles allowing targeting of said physiologically effective substance(s) to a specific site within said mammalian body and/or a surfactant coating on said nanoparticles, said nanoparticles optionally being provided within a physiologically acceptable carrier and/or diluent allowing the delivery of said nanoparticles to the target within said mammal after administration, in an amount effective for the treatment of cancer.
  • the administration is an i.v. administration. It is particularly preferred that the treatment is a treatment of brain cancer, e. g. in mammals as for example humans.
  • the invention is further exemplified by the subsequent example which, however, should not be understood to limit the invention.
  • the anti-tumor effect of doxorubicin preparations was tested in rats with an intracranially transplanted glioblastoma 101/8. This tumor is known to have a substantial number of receptors to the epidermal growth factor.
  • mice were treated with 1.5 mg/kg x 3 of doxorubicin which makes a total course dose of 4.5 mg/kg (the total dose for mice is usually 7 to 8 mg/kg).
  • the drugs were administered i/v on the day 2 (48 h after implantation of the tumor), day 5 and day 8 after tumor implantation.
  • Drug preparations were administered as usual in saline or in 1 % Tween R 80 .
  • the suspension was added with 1 % Tween R 80 with stirring. The mixture was incubated for 2 h.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne l'utilisation de nanoparticules chargées de médicament dans la préparation d'un médicament anticancéreux, destiné en particulier au traitement du cancer du cerveau, et plus particulièrement, du cancer du cerveau chez les humains. L'invention concerne également un procédé permettant de traiter le cancer du cerveau, en particulier le cancer du cerveau chez les humains, en administrant une quantité efficace de nanoparticules contenant une substance active dans le traitement anticancéreux ou qui possède des effets immunosuppresseurs.
PCT/EP1999/003838 1999-06-02 1999-06-02 Utilisation de nanoparticules chargees de medicament dans le traitement anticancereux Ceased WO2000074658A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99926509A EP1100475A1 (fr) 1999-06-02 1999-06-02 Utilisation de nanoparticules chargees de medicament dans le traitement anticancereux
JP2001501195A JP2003501379A (ja) 1999-06-02 1999-06-02 ガン治療のための薬剤を充填したナノパーティクルの使用
PCT/EP1999/003838 WO2000074658A1 (fr) 1999-06-02 1999-06-02 Utilisation de nanoparticules chargees de medicament dans le traitement anticancereux
AU43734/99A AU4373499A (en) 1999-06-02 1999-06-02 Use of drug-loaded nanoparticles for the treatment of cancers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1999/003838 WO2000074658A1 (fr) 1999-06-02 1999-06-02 Utilisation de nanoparticules chargees de medicament dans le traitement anticancereux

Publications (1)

Publication Number Publication Date
WO2000074658A1 true WO2000074658A1 (fr) 2000-12-14

Family

ID=8167319

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/003838 Ceased WO2000074658A1 (fr) 1999-06-02 1999-06-02 Utilisation de nanoparticules chargees de medicament dans le traitement anticancereux

Country Status (4)

Country Link
EP (1) EP1100475A1 (fr)
JP (1) JP2003501379A (fr)
AU (1) AU4373499A (fr)
WO (1) WO2000074658A1 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004017945A1 (fr) * 2002-07-29 2004-03-04 Nanodel Technologies Gmbh Nanoparticules pour administration d'adn a un organe cible
WO2003028700A3 (fr) * 2001-09-28 2004-06-17 Solubest Ltd Nanoparticules solubles dans l'eau constituees de materiaux hydrophiles et hydrophobes et dispositif et procede de fabrication de celles-ci
JP2004531545A (ja) * 2001-05-05 2004-10-14 エルテーエス ローマン テラピー−ジステーメ アーゲー アポリポタンパク質ｅと結合するタンパク質からなる血液脳関門を通過するナノ粒子及びその製造方法
US6878693B2 (en) 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
US7025991B2 (en) 1997-06-13 2006-04-11 Nanodel Technologies Gmbh Drug targeting system, method of its preparation and its use
WO2006097725A3 (fr) * 2005-03-15 2006-12-21 Queen Mary & Westfield College Preparations pharmaceutiques comprenant des microparticules penetrant les neurones
US7153525B1 (en) 2000-03-22 2006-12-26 The University Of Kentucky Research Foundation Microemulsions as precursors to solid nanoparticles
WO2007073932A3 (fr) * 2005-12-27 2007-09-27 Lohmann Therapie Syst Lts Systeme support a base de proteines pour vaincre la resistance de cellules tumorales
EP1985286A1 (fr) * 2007-04-24 2008-10-29 Biocompatibles UK Limited Microsphères pour le traitement de tumeurs cérébrales
WO2010040173A1 (fr) * 2008-10-08 2010-04-15 Commonwealth Scientific And Industrial Research Organisation Procédé d'administration d'agents fonctionnels à travers la barrière hémato-encéphalique
US7763663B2 (en) 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US8287877B2 (en) 2000-09-14 2012-10-16 PX Biosolutions Pty Ltd. Composition comprising immunogenic microparticles
US10532019B2 (en) 2005-12-01 2020-01-14 University Of Massachusetts Lowell Botulinum nanoemulsions
US11311496B2 (en) 2016-11-21 2022-04-26 Eirion Therapeutics, Inc. Transdermal delivery of large agents

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2007037474A1 (ja) 2005-09-30 2009-04-16 Ｔｔｉ・エルビュー株式会社 ナノパーティクルに封入された薬物投与のためのイオントフォレーシス用電極構造体およびそれを用いたイオントフォレーシス装置
WO2007079193A2 (fr) 2005-12-30 2007-07-12 Tti Ellebeau, Inc. Systèmes iontophorétiques, dispositifs et procédés d'administration de principes actifs dans une interface biologique
EP2072079A1 (fr) 2006-10-10 2009-06-24 TTI ellebeau, Inc. Dispositif d'ionophorese de type dent artificielle
JP5201763B2 (ja) * 2007-02-28 2013-06-05 昇一 城武 異なる平均粒径サイズの粒子からなる混合微粒子カプセルの製造方法
GB201209517D0 (en) * 2012-05-29 2012-07-11 Univ Birmingham Nanoparticles
CN103623424B (zh) * 2012-08-24 2016-08-03 复旦大学 一种基于聚甲基丙烯酸酯的脑靶向基因递释系统

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5133908A (en) * 1986-12-31 1992-07-28 Centre National De La Recherche Scientifique (Cnrs) Process for the preparation of dispersible colloidal systems of a substance in the form of nanoparticles
WO1995022963A1 (fr) * 1994-02-28 1995-08-31 Medinova Medical Consulting Gmbh Systeme de ciblage d'un medicament, procede de preparation et utilisation de ce medicament
WO1998056361A1 (fr) * 1997-06-13 1998-12-17 Medinova Medical Consulting Gmbh Systeme de ciblage de medicament, procede permettant de le preparer et son utilisation
DE19745950A1 (de) * 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5133908A (en) * 1986-12-31 1992-07-28 Centre National De La Recherche Scientifique (Cnrs) Process for the preparation of dispersible colloidal systems of a substance in the form of nanoparticles
WO1995022963A1 (fr) * 1994-02-28 1995-08-31 Medinova Medical Consulting Gmbh Systeme de ciblage d'un medicament, procede de preparation et utilisation de ce medicament
WO1998056361A1 (fr) * 1997-06-13 1998-12-17 Medinova Medical Consulting Gmbh Systeme de ciblage de medicament, procede permettant de le preparer et son utilisation
DE19745950A1 (de) * 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
COUVREUR P, ET AL.: "Toxicity of polyalkylcyanoacrylate nanoparticles II: doxorubicin-loaded nanoparticles", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 71, no. 7, 1982, ISSN 0022-3549, pages 790 - 792, XP000783921 *
RESZKA R, ET AL.: "Body distribution of free, liposomal and nanoparticle-associated mitoxantrone in B16-melanoma-bearing mice", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 280, no. 1, 1997, ISSN 0022-3565, pages 232 - 237, XP002129865, Retrieved from the Internet <URL:http://jpet.aspetjournals.org/cgi/reprint/280/1/232> [retrieved on 20000207] *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7025991B2 (en) 1997-06-13 2006-04-11 Nanodel Technologies Gmbh Drug targeting system, method of its preparation and its use
US7153525B1 (en) 2000-03-22 2006-12-26 The University Of Kentucky Research Foundation Microemulsions as precursors to solid nanoparticles
US8287877B2 (en) 2000-09-14 2012-10-16 PX Biosolutions Pty Ltd. Composition comprising immunogenic microparticles
US8846026B2 (en) 2000-09-14 2014-09-30 Px Biosolutions Pty Ltd Composition comprising immunogenic microparticles
JP2004531545A (ja) * 2001-05-05 2004-10-14 エルテーエス ローマン テラピー−ジステーメ アーゲー アポリポタンパク質ｅと結合するタンパク質からなる血液脳関門を通過するナノ粒子及びその製造方法
AU2002362475B2 (en) * 2001-09-28 2008-07-10 Solubest Ltd. Water soluble nanoparticles of hydrophilic and hydrophobic active materials
US7081450B2 (en) 2001-09-28 2006-07-25 Solubest Ltd. Water soluble nanoparticles of hydrophilic and hydrophobic active materials and an apparatus and method for their production
US6878693B2 (en) 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
WO2003028700A3 (fr) * 2001-09-28 2004-06-17 Solubest Ltd Nanoparticules solubles dans l'eau constituees de materiaux hydrophiles et hydrophobes et dispositif et procede de fabrication de celles-ci
US7763663B2 (en) 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
WO2004017945A1 (fr) * 2002-07-29 2004-03-04 Nanodel Technologies Gmbh Nanoparticules pour administration d'adn a un organe cible
US7402573B2 (en) 2002-07-29 2008-07-22 Nanodel Technologies Gmbh Use of nanoparticles for the DNA administration to a target organ
JP2006500015A (ja) * 2002-07-29 2006-01-05 ナノデル テヒノロギーズ ゲーエムベーハー 標的器官へのｄｎａ投与のためのナノ粒子の使用
WO2006097725A3 (fr) * 2005-03-15 2006-12-21 Queen Mary & Westfield College Preparations pharmaceutiques comprenant des microparticules penetrant les neurones
US10532019B2 (en) 2005-12-01 2020-01-14 University Of Massachusetts Lowell Botulinum nanoemulsions
US10576034B2 (en) 2005-12-01 2020-03-03 University Of Massachusetts Lowell Botulinum nanoemulsions
WO2007073932A3 (fr) * 2005-12-27 2007-09-27 Lohmann Therapie Syst Lts Systeme support a base de proteines pour vaincre la resistance de cellules tumorales
EP1985286A1 (fr) * 2007-04-24 2008-10-29 Biocompatibles UK Limited Microsphères pour le traitement de tumeurs cérébrales
WO2010040173A1 (fr) * 2008-10-08 2010-04-15 Commonwealth Scientific And Industrial Research Organisation Procédé d'administration d'agents fonctionnels à travers la barrière hémato-encéphalique
US11311496B2 (en) 2016-11-21 2022-04-26 Eirion Therapeutics, Inc. Transdermal delivery of large agents

Also Published As

Publication number Publication date
JP2003501379A (ja) 2003-01-14
EP1100475A1 (fr) 2001-05-23
AU4373499A (en) 2000-12-28

Similar Documents

Publication Publication Date Title
WO2000074658A1 (fr) Utilisation de nanoparticules chargees de medicament dans le traitement anticancereux
CN1210020C (zh) 释放抗癌剂的生物降解微球在治疗成胶质细胞瘤方面的用途
US20100074927A1 (en) Delivery of therapeutic compounds via microparticles or microbubbles
KR100471672B1 (ko) 시스플라틴을 함유하는 마이크로그래뉼
EP2063881B1 (fr) Composition et méthode pour administrer efficacement et sans danger un halopyruvate pour traiter un cancer
US20110195030A1 (en) Nanoparticle compositions comprising liquid oil cores
CN1139380A (zh) 控释制剂
EP2262478A2 (fr) Donneurs d oxyde nitrique activés et méthodes de fabrication et d utilisation associées
CN114469892A (zh) 制备负载双硫仑的纳米颗粒的溶剂蒸发法
US20130189364A1 (en) Compositions and methods of potentiating adjuvant pharmaceuticals targeting latent viral infections
KR20160142283A (ko) 아연 프로토포르피린의 마이크로입자 전달용 제형물
JP5642892B2 (ja) 多形膠芽腫の治療のためのマシテンタンを含有する組み合わせ剤
Yemisci et al. Treatment of malignant gliomas with mitoxantrone-loaded poly (lactide-co-glycolide) microspheres
WO2016020697A1 (fr) Compositions pharmaceutiques de monoparticules polymères
US20070042046A1 (en) Methods for the treatment of cancer
AU2005284909B2 (en) Delivering iron to an animal
CZ20023333A3 (cs) Léčivo pro léčení rakoviny
Truter et al. Assessment of the antitumour activity of targeted immunospecific albumin microspheres loaded with cisplatin and 5‐fluorouracil: toxicity against a rodent ovarian carcinoma in vitro
CN100366253C (zh) 1,2,4-苯并三嗪氧化物制剂
Wahlberg et al. Polymeric controlled-release amsacrine chemotherapy in an experimental glioma model
US20230225983A1 (en) Drug comprising plga nanoparticles loaded with cape targeted with angiopep-2 peptide
JP2022517352A (ja) マイトマイシンｃのリポソーム化プロドラッグを含むリポソーム組成物および製造法
Gvozdetskiy Drug Delivery Systems Meeting Quality
Pandya et al. Nanoparticles containing nitric oxide donor with antileishmanial agent for synergistic effect against visceral leishmaniasis
WO2007014150A2 (fr) Procede d&#39;administration de liposomes contenant des oligonucleotides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LV MD MG MK MN MW MX NZ PL RO RU SD SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999926509

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 09774181

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999926509

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWR Wipo information: refused in national office

Ref document number: 1999926509

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999926509

Country of ref document: EP